Literature DB >> 108733

Enhanced 5-hydroxytryptamine-mediated behavioural responses in rats following repeated electroconvulsive shock: relevance to the mechanism of the antidepressive effect of electroconvulsive therapy.

D W Costain, A R Green, D G Grahame-Smith.   

Abstract

Treatment of rats with one electroconvulsive shock (ECS) per day for 10 days enhanced the hyperactivity syndrome produced by administration of tranylcypromine (10 mg kg-1) and L-tryptophan (50 mg kg-1) given 24 h after the final shock. Similar enhancement was seen whether the shock was alternating sinusoidal or direct current (fractionated), whether it was given through unilaterally or bilaterally placed electrodes and whether or not a neuromuscular blocking agent (fazadinium) was used. Five shocks spread over 10 days or 8 shocks spread over 17 days were similarly effective, whilst 8 shocks in 1 day were ineffective. Therefore when ECS are given to rats in ways similar to those in which electroconvulsive therapy is given to patients with depression, enhancement of behavioural responses to increased 5-HT function is produced.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 108733     DOI: 10.1007/bf00426732

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  14 in total

1.  Controlled trial of straight and modified electroplexy.

Authors:  C P SEAGER
Journal:  J Ment Sci       Date:  1959-10

2.  Unilateral electro-convulsive therapy.

Authors:  N P LANCASTER; R R STEINERT; I FROST
Journal:  J Ment Sci       Date:  1958-01

3.  Further observations on the effect of repeated electroconvulsive shock on the behavioural responses of rats produced by increases in the functional activity of brain 5-hydroxytryptamine and dopamine.

Authors:  A R Green; D J Heal; D G Grahame-Smith
Journal:  Psychopharmacology (Berl)       Date:  1977-04-29       Impact factor: 4.530

4.  The Royal College of Psychiatrists' Memorandum on the use of Electroconvulsive Therapy. Part 1-Effectiveness of ECT-a review of the evidence.

Authors: 
Journal:  Br J Psychiatry       Date:  1977-09       Impact factor: 9.319

5.  Electroconvulsive shock increases the behavioural responses of rats to brain 5-hydroxytryptamine accumulation and central nervous system stimulant drugs.

Authors:  J P Evans; D G Grahame-Smith; A R Green; A F Tordoff
Journal:  Br J Pharmacol       Date:  1976-02       Impact factor: 8.739

6.  The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats.

Authors:  A R Green; D G Grahame-Smith
Journal:  Neuropharmacology       Date:  1974-11       Impact factor: 5.250

7.  A comparison of techniques in electro-convulsive therapy.

Authors:  M Valentine; K M Keddie; D Dunne
Journal:  Br J Psychiatry       Date:  1968-08       Impact factor: 9.319

8.  Long-term effects of electroconvulsive shock therapy on synthesis, turnover and uptake of brain monoamines.

Authors:  K Modigh
Journal:  Psychopharmacology (Berl)       Date:  1976-09-17       Impact factor: 4.530

9.  Mechanism of the antidepressant action of electroconvulsive therapy.

Authors:  D G Grahame-Smith; A R Green; D W Costain
Journal:  Lancet       Date:  1978-02-04       Impact factor: 79.321

10.  Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan.

Authors:  D G Grahame-Smith
Journal:  J Neurochem       Date:  1971-06       Impact factor: 5.372

View more
  13 in total

Review 1.  Antidepressants and serotonergic neurotransmission: an integrative review.

Authors:  P Willner
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 2.  Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system.

Authors:  G B Baker; A J Greenshaw
Journal:  Cell Mol Neurobiol       Date:  1989-03       Impact factor: 5.046

3.  Changes in the behavioural response to a TRH analogue following chronic amitriptyline treatment and repeated electroconvulsive shock in the rat.

Authors:  G W Bennett; A R Green; C Lighton; C A Marsden
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

4.  Some anticonvulsant drugs alter monoamine-mediated behaviour in mice in ways similar to electroconvulsive shock; implications for antidepressant therapy.

Authors:  A R Green; P Johnson; J A Mountford; V L Nimgaonkar
Journal:  Br J Pharmacol       Date:  1985-02       Impact factor: 8.739

5.  Brain and serum calcium concentrations following electroconvulsive shock or bicuculline-induced convulsions in rats.

Authors:  J M Bowdler; A R Green; F Rawle
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

6.  beta-Adrenoceptor agonists enhance 5-hydroxytryptamine-mediated behavioural responses.

Authors:  P J Cowen; D G Grahame-Smith; A R Green; D J Heal
Journal:  Br J Pharmacol       Date:  1982-06       Impact factor: 8.739

7.  A comparison of various antidepressant drugs demonstrates rapid desensitisation of alpha 2-adrenoceptors exclusively by sibutramine hydrochloride.

Authors:  D J Heal; M R Prow; J Gosden; G P Luscombe; W R Buckett
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

8.  Ect and platelet 5ht uptake in major depression.

Authors:  P K Dalal; N Lal; J K Trivedi; P K Seth; A K Agarwal; A Khalid
Journal:  Indian J Psychiatry       Date:  1997-10       Impact factor: 1.759

9.  Active platelet 5-ht uptake in depressives treated with impramine and ect.

Authors:  P K Dalal; N Lal; J K Trivedi; P K Seth; A K Agarwal; A Khalid
Journal:  Indian J Psychiatry       Date:  1998-01       Impact factor: 1.759

10.  Increased 5-HT2 receptor number in brain as a probable explanation for the enhanced 5-hydroxytryptamine-mediated behaviour following repeated electroconvulsive shock administration to rats.

Authors:  A R Green; P Johnson; V L Nimgaonkar
Journal:  Br J Pharmacol       Date:  1983-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.